EVH Stock Recent News

Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics Acquisition expected to benefit health plans, clinicians, and members WASHINGTON , June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"), (NYSE: EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a proven software platform that leverages the latest advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applicati

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago.

The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript

Evolent Health, Inc. (NYSE:EVH ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer, Co-Founder & Board Member John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Kevin Caliendo - UBS Unknown speaker - Guggenheim Partners Charles Rhyee - TD Cowen Jeff Garro - Stephens Inc Richard Close - Canaccord Genuity David Larsen - BTIG Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Operator Welcome to the Evolent Earnings Conference Call for the quarter ended September 30th, 2023. As a reminder, this conference call is being recorded.

Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.59 per share a year ago.

WASHINGTON , Oct. 10, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2023 financial results on Thursday, Nov. 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com.

Evolent Health (EVH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.